{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The number of participants with febrile neutropenia, considering all chemotherapy cycles.","groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.\n\nF-627: single dose pre-filled syringe","id":"OG000","title":"F-627"},{"description":"6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles\n\nNeulasta: single dose pre-filled syringe","id":"OG001","title":"Neulasta"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT (Intent-to-Treat) population","reportingStatus":"POSTED","timeFrame":"across all 4 chemotherapy cycles (average 84 days)","title":"The Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.","type":"SECONDARY","unitOfMeasure":"Participants"}